CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

« Robotically Driven System Could Reduce Cost of Discovering Drugs

$2M for Speech and Brain Rehab App awarded to BU Spinout Constant Therapy »

CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts

March 15, 2016 by 2012pharmaceutical

CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts

Reporter: Aviva Lev-Ari, PhD, RN

Register today and join over 100 of your colleagues. See below

CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts

Register | View agenda | Download final brochure

healthtech.com/oligonucleotide/

Corporate Support Sponsor

Oligonucleotide-based therapeutics have long formed the third major drug development platform, specifically focused on modulating gene expression by targeting RNA or the genome itself. A key distinguishing attribute of nucleic acids as therapeutic agents is their ability to access the “undruggable” space left by small molecules and biologics, allowing drug developers to address a wider range of diseases, and particularly those with limited or no therapeutic options. This has generated significant interest in this field; however, first generation molecules exhibiting potency and safety issues have hindered the potential of oligonucleotide therapies dramatically impacting the drug development landscape. Recent advances in nucleic acid chemistry and delivery to improve stability, bioavailability, specificity and potency are now driving the rapid development and clinical evaluation of a new generation of therapies poised for success.

The Oligonucleotide Therapeutics and Delivery conference, April 4-5, in Cambridge, MA will gather leading drug developers and discovery scientists to discuss technological and scientific advances in oligonucleotide-based therapeutics

Topics Include

Advances in Oligonucleotide Therapeutics
Synthesis and Medicinal Chemistry
G-Quadruplex-Forming Oligonucleotides
Cancer Immunotherapy and Combinations
Immuno-Oncology and Oligonucleotide Intellectual Property
Antiviral Development
Advances in RNA Therapeutics and Delivery
Delivery to the CNS
Novel and Emerging Approaches for In Vivo Delivery

Featured Short Course*

Oligonucleotide Therapeutics: From Discovery to Manufacturing

Sunday, April 3rd | 5:00 – 8:00 pm

Instructor: Dmitry Samarsky, Ph.D., Senior Vice President, Technology & Global Business Development, OliX Pharmaceuticals, Inc.

*separate registration required

Keynote Speaker

Muthiah (Mano) Manoharan, Ph.D., Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals, Inc.

Featured Speakers

Art Krieg, M.D., Founder and CEO, Checkmate Pharma

Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University, South Korea; CEO, OliX Pharmaceuticals

Punit Seth, Ph.D., Executive Director, Medicinal Chemistry, Isis Pharmaceuticals

Here is a partial list of confirmed participants

Company

A STAR

AccuRna Inc

Advanced Cancer Therapeutics

AIC Inc

Alexion Pharmaceuticals Inc

Alios BioPharma Inc

Alnylam Pharmaceuticals

AM Biotechnologies LLC

Arcturus Therapeutics Inc

Arrowhead Research Corp

Astellas Venture Mgmt LLC

Avidity NanoMedicines

Axolabs GmbH

Bio Path Holdings Inc

Bracco Diagnostics

Brigham & Womens Hospital

Bristol Myers Squibb Co

Brown Univ

Checkmate Pharmaceuticals

Corden Pharma

CureVac GmbH

Dicerna Pharmaceuticals Inc

Eisai Inc

Evercyte GmbH

Exicure

George Mason Univ

Guangzhou RiboBio Co Ltd

Harvard Univ

Idera Pharmaceuticals Inc

InteRNA Technologies BV

Ionis Pharmaceuticals Inc

Johns Hopkins Univ

LGC Biosearch Technologies

Matinas Biopharma Inc

Mayo Clinic

MirImmune LLC

MiRNA Therapeutics Inc

Mitsubishi Tanabe Pharma Dev America Inc

MPEG LA

NITTO DENKO Avecia Inc

Life Therapeutics

Nubad LLC

Nutter McClennen & Fish LLP

Ono Pharma USA Inc

Ono Pharmaceutical

Pfizer Worldwide R&D

Quark Pharmaceuticals

RaNA Therapeutics Inc

REPLIcor Inc

Rice Univ

Roche Innovation Ctr Copenhagen

RXi Pharmaceuticals Corp

Sarepta Therapeutics

Sevident Inc

Silence Therapeutics AG

SomaLogic Inc

Sungkyunkwan Univ

The Solution Lab

Tokyo Medical & Dental Univ

Univ of California Los Angeles

Univ Of Massachusetts

Univ of Miami

Univ of Missouri Columbia

Univ of North Carolina Chapel Hill

Waters Corp

Wave Life Sciences

Title

Sr Principal Investigator

Dir

CSO

Dir

Assoc Dir

Assoc Dir Upstream Dev

Dev Scientist I

Dev Scientist II

Development Scientist II

Sr. Research Investigator II

Founder & CSO

Principal Research Assoc

Sr VP Drug Discovery

Dir R&D

CSO & COO

CSO

Assoc Investment Dir

Exec VP R&D

Managing Dir

Dir Corp Dev

Sr Research Scientist

Assoc Prof Medicine

Assoc Dir

Instructor

CEO

Head Bus Dev & Product Mgmt

CSO

Research Assoc

Scientist I

Sr Dir

Sr Research Assoc

Principal Scientist

PhD

CEO

Research Dir

Exec VP Technology & Bus Dev

PhD Candidate

President

CEO

Exec Dir Medicinal Chemistry

Asst Prof

Technical Sales Specialist

CTO

Assoc Prof & Consultant

CSO

Exec VP & CSO

Sr Mgr

Exec Dir Biotechnology Licensing

Proposal Writer

VP Dev

CEO

CSO

Partner & Patent Attorney

Sr Mgr

Sr Dir

CSO

CEO

VP Chemistry

CSO & VP

PostDoc

Sr Scientist

Chief Dev Officer

VP Discovery Research

President

Dir Formulation

Dir of Specialty Chemistry

Assoc Prof

Consultant

Prof

Project Asst Prof

Dir

Prof

Prof Microbiology & Immunology

Asst Research Prof

Prof

Sr Bus Dev Mgr

Sr Market Mgr

Sr Scientist

Sr VP & Head

Featured Podcast

The Resurgence of Oligonucleotide Therapeutics:
A Podcast Discussing Challenges, Advances, and an Outlook for Success

Click here to access podcast

SOURCE

From: Oligonucleotide Therapeutics and Delivery conference <richh@healthtech.com>

Date: Tuesday, March 15, 2016 at 1:11 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: You still have time to register, less than three weeks away

Posted in CRISPR/Cas9 & Gene Editing, Oligonucleotide Therapeutics & Delivery | Tagged Oligonucleotide Therapeutics & Delivery | Leave a Comment

Comments RSS

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts

CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts

Like this:

Leave a Reply Cancel reply

Follow Blog via Email

Recent Posts

Archives

Categories

Meta

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts

CHI’s Inaugural Oligonucleotide Therapeutics & Delivery | April 4-5, 2016 | Hyatt Regency | Cambridge, Massachusetts

Share this:

Like this:

Leave a Reply Cancel reply

Follow Blog via Email

Recent Posts

Archives

Categories

Meta